<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG2>
<DESCRIPTION>Risk of serious hypotension (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of serious hypotension (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
